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1. Introduction  
Human pluripotential stem cells, including both embryonic stem cells (ES cells) and induced 
pluripotent stem cells (iPS cells), possess self-renewing potency or the ability to differentiate 
into virtually any type of somatic cell. These features make them particularly advantageous 
as sources from which to generate specific types of human tissue cells in vitro for use in drug 
development and regenerative medicine. In most cases, however, human pluripotential cell 
lines and especially human ES cells can only be used in cell-based applications because of 
ethical issues. Animal models are therefore sought as an alternative to using human cells. 
An increasingly popular non-human primate model is the common marmoset (Callithrix 
jacchus). The recent successful creation of lentivirus-mediated transgenic marmosets 
provides a new animal model for human disease offering the powerful advantage of a close 
genetic relationship with humans (Sasaki et al., 2009), though this technique is not yet 
sufficiently developed for common use, and the numbers of monkeys available for 
experiments are limited. Mouse ES cells, meanwhile, still have great value as a research tool, 
even after the development of human pluripotent cells, as they can be used to create 
chimeric mice, achieve germline transmission, and generate normal offspring. 
The available genetic engineering technologies often employ an embryonic manipulation 
approach in mice, using mouse ES cells to examine the gain-of-function or loss-of-function 
effects associated with certain chromosomal regions in vivo. Recently, we have developed 
chromosome elimination cassettes (CEC) using a Cre-inverted loxP system that was first 
used in mouse ES cells. In this system, transient cre expression can initiate immediate 
chromosomal loss over the course of a few cell cycles in the recombinant cells. This 
technology was developed to clarify chromosomal function through observing loss-of-
function at the chromosomal level. In mammalian cells, chromosome composition and gene 
dosage are kept stable because large chromosome-wide deletions are usually fatal. 
Accordingly, we first applied the Cre-inverted loxP system to tetraploid cells composed of 
mouse ES cells fused with mouse somatic cells to generate conditions conducive to large-
scale chromosomal imbalance. The CEC-tagged chromosomes could be targets of Cre-
dependent chromosome elimination. In addition, we have demonstrated that the Cre-
inverted loxP system enhances cohesion between a loxP site and an adjacent inverted loxP, 
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which induces a remarkable degree of spontaneous mitotic recombination around loxP sites. 
These characteristics may also help us to resolve the mechanisms involved in spontaneous 
mitotic recombination events leading to chromosomal deletion during tumorigenesis. This 
review discusses the development of the chromosome elimination method over the last few 
years and provides examples of the emerging practical use of mouse ES cell lines containing 
CEC-tagged chromosomes as a chromosome engineering technology. 
Recent advances in the opposite direction, that is, toward the insertion of chromosomes into 
cells as a chromosome engineering technology, are also discussed here. Human artificial 
chromosome (HAC) vectors have been used to transport intact foreign chromosomal 
segments. The Cre-loxP system is frequently employed in this form of chromosome transfer 
technology as well. HAC contains an acceptor loxP that promotes insertion of the 
chromosomal region through chromosome translocation with the donor loxP-tagged 
chromosome (Smith et al., 1995). If undesired chromosomal regions exist at the ends of the 
loxP-tagged donor chromosome, the regions can be trimmed using telomere-directed 
truncation technology; for the efficient application of this technique, chicken DT40 cells are 
often used as high homologous recombination-proficient cells. At the end of this process, the 
desired region is introduced into the final host cells (Dieken et al., 1996; Kuroiwa et al., 
1998). In any step of this process toward the production of the final transformants, an HAC 
can be sequentially transferred from one type of cell to the other by means of the microcell-
mediated chromosome transfer (MMCT) technique (Kuroiwa et al., 2000). MMCT requires a 
high level of skill, but can be used to produce 1:1 cell fusion products between micro-cells, 
which contain a recombinant chromosome, and host cells at high frequencies. Though some 
trials have been started, this remains a significant problem in chromosome transfer 
technology (Katoh et al., 2010). As a consequence, trans-chromosomal mice generated by 
germline transmission of an HAC have been created via the formation of chimeric mice with 
mouse ES cells that stably possess a defined chromosomal region on an HAC (Kuroiwa et 
al., 2002). Using this chromosome transfer technology with pluripotential cells offers 
advantages supporting the identification of the functions of given chromosome segments on 
the basis of gain-of-function and the repair of impaired genome-wide functions in the host 
cells. By observing the functional differences between wild-type cells and transformants, 
researchers can identify the responses to given stimuli and address these effects via 
chromosome transfer. These cells are not expected to over express any particular molecule 
on the transferred chromosome and are thought to exhibit more-or-less physiological 
responses to transcriptional regulation in-vivo. Accordingly, chromosome-transferred cells 
might sometimes constitute a more useful assay system than single-gene recombinant cells 
that highly express a single target molecule. Moreover, parallel inheritance of a human 
chromosome by cells from another animal species after elimination of the parallel 
chromosomal region makes it possible to create humanized animals. 
The physiological relevance of biological analyses using CEC or HAC technology is actually 
demonstrated by the epigenetic reprogramming activity that occurs in host pluripotent cells. 
Reprogramming factors operating in pluripotent cells can impose epigenetic modifications 
on foreign somatic chromosomes that have been introduced by cell fusion, making their 
cells equivalent to host pluripotent cells. Without this activity, introduced chromosome 
segments would never be able to behave like their homologues or orthologues in the given 
cells in vitro and in vivo. Our previous important findings on the epigenetic reprogramming 
potencies working in mouse ES cells are discussed first. 
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2. Epigenetic reprogramming potencies in mouse ES cells 
In keeping with the classic epigenetic landscape model, it was long believed that epigenetic 
marks were placed into the genome step by step during a developmental program and that 
the epigenetics of somatic nuclei would never revert to a pluripotential, multipotential, or 
bipotential state. The successful creation of adult normal frogs by nuclear transfer from 
highly specialized tadpole intestinal cells into ultraviolet-light-irradiated oocytes clearly 
demonstrated that developmental programs can be completely reversed (Gurdon, 1962). The 
first successfully cloned mammal was made by fusing a G0 cell with an enucleated 
unfertilized oocyte (Wilmut et al., 1997). As technology improved, it became possible to 
replace a mouse oocyte nucleus with a mouse somatic nucleus through enucleation; this led 
to the successful creation of cloned mice (Wakayama et al., 1998). This process is called 
somatic-cell nuclear transfer, and is now widely used. Complete epigenetic reprogramming 
in vivo through nuclear transfer creates another means by which the specific genotype of an 
animal can be propagated in the absence of mating.  
Animal cloning suggested that epigenetic restoration was occurring in the somatic nuclei 
during embryonic development, but the these epigenetic changes were first analytically 
visualized through cell fusion between somatic cells and undifferentiated cells. Every female 
mammalian somatic cell possesses an inactivated X chromosome as a gene dosage 
compensation mechanism between XX female cells and XY male cells. To maintain X 
chromosome inactivation, numerous molecules, including the non-coding RNA Xist, are 
accumulated on the inactive X chromosome in cis. Moreover, DNA cytosine methylation of 
the Xist gene is kept at a low level on the inactivated somatic X chromosome. The somatic X 
chromosome is converted from an inactive state to an active state through cell fusion with 
mouse embryonic carcinoma cells (EC cells), in which case the fused cells acquire 
undifferentiated-cell morphology (Takagi et al., 1983).  
As a next step, we demonstrated that de novo DNA cytosine methylation of the Xist gene 
might silence the Xist allele on the previously inactivated somatic X chromosome and 
initiate conversion of the X chromosome from an inactive state to an active state in somatic 
hybrid cells between certain kinds of EC cells and female somatic cells (Mise et al., 1996). By 
that time, however, we were asking whether the mouse EC cells had lost an important factor 
required for the maintenance of the X inactivation state through carcinogenesis or possessed 
dominant factors that converted the somatic nucleus to a host EC cell-like nucleus. To 
resolve this question, we designed a cell fusion experiment involving mouse embryonic 
germ cells (EG cells) and mouse somatic cells (Tada et al., 1997). The mouse EG cells, 
derived from primordial germ cells from embryonic-day (e)11.5 to e12.5 female embryos, 
had lost the epigenetic differences, also known as genomic imprinting, between the 
homologous chromosomes derived from the two parents. Inactivation marks on the X-
chromosome and genome-wide CpG methylation had already been eliminated from the 
mouse gonadal EG cells. These cells could contribute to mouse development, but the 
resulting chimeric embryos were abnormal because of the deletion of the previous genomic 
imprints (Tada et al., 1998). Thus, unlike mouse EC cells, mouse EG cells are not derived 
through carcinogenesis, and they maintain a set of the epigenetic properties of the original 
cells. Several important characteristics of the epigenetic reprogramming activities working 
in embryonic pluripotent cells were first analytically demonstrated at the molecular level 
through cell fusion experiments using gonadal mouse EG cells and mouse somatic cells. The 
mouse EG cells contribute pluripotency to the resulting somatic nuclei, which in turn grants 
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them several other EG cell-like characteristics, including the following: (1) reactivation of 
inactivated X chromosome derived from female somatic cells, (2) competence for embryonic 
development, (3) deletion of genome-wide DNA cytosine methylation, (4) deletion of 
methylation marks from several imprinted and non-imprinted genes, and (5) demonstrable 
reactivation of the repressed paternally imprinted allele of Peg1/Mest.  
We then showed that somatic cells can acquire a pluripotent state after being fused with 
mouse ES cells (Tada et al., 2001). Using thymocytes from female mice that contained a GFP 
reporter transgene driven by the promoter of mouse Oct4, we monitored Oct4 reactivation 
by an Oct4–gfp reporter. In contrast to germ cells, mouse ES cells do not possess 
demethylation activity for imprinted genes in fused tetraploid cells, as far as we could 
determine. Interestingly, methylation imprints on mouse ES cell chromosomes were erased 
in the hybrid cells made from mouse gonadal EG cells. This evidence shows that mouse EG 
cells possess dominant factors leading to the erasure of methylation imprints. The latter 
fusion experiments included our first use of intersubspecies hybrid cells, made from Mus 
musculus domesticus ES cells and Mus musculus molossinus thymocytes (Tada et al., 2003; 
Kimura et al., 2004; Kimura et al., 2002; Hatano et al., 2005). Frequent DNA sequence 
polymorphisms between these two subspecies allowed us to monitor the origin of the RNA 
and DNA derived from the somatic nuclei of the tetraploid hybrid cells. Using this mouse 
ES cell-somatic cell fusion system, we demonstrated (6) reactivation of some pluripotency-
associated genes derived from somatic genomes (i.e., Oct4, Nanog, and Tsix) and (7) 
conversion of histone modification of somatic cell-derived chromatin to a pluripotent state. 
The reprogrammed somatic genomes in the hybrid cells made from mouse ES cells became 
hyperacetylated at histones H4 and H3 and globally dimethylated and trimethylated, with 
respect to the lysine residue K4, at H3. Such epigenetics are known as typical modifications 
for transcriptionally active regions. Later, another group demonstrated that overexpression 
of Nanog substantially enhanced fusion-based nuclear reprogramming (Silva et al., 2006). 
Nanog is known to be an important transcriptional factor involved in maintaining 
pluripotency (Chambers et al., 2003; Mitsui et al., 2003). We have previously shown that 
Nanog expression is controlled by Oct4 and Sox2 (Kuroda et al., 2006), which regulate the 
pluripotency of mouse ES cells in a dose-dependent manner (Hatano et al., 2005). Thus, we 
expected that two copies of endogenous Nanog mRNA might not be sufficient to make the 
tetraploid cells pluripotent during the initial full cell cycles after cell fusion with somatic 
cells when extrinsic Nanog was fully reprogrammed. We addressed this question by 
attempting the complete elimination of two copies of mouse ES cell-derived Nanog-bearing 
chromosome 6s in ES cell-somatic cell hybrid cells (Matsumura et al., 2007). The results 
clearly demonstrated that Nanog expression from reprogrammed somatic genomes could 
efficiently maintain pluripotency in mouse ES cell-somatic cell hybrid cells, but that at least 
three out of four copies of chromosome 6s were required to keep tetraploid cells pluripotent. 
This will be discussed in greater detail below. 
ES cell-specific epigenetic profiles are predominantly regulated by intrinsic factors, so that 
the host cell’s epigenotypes can be exposed to foreign DNAs and histones in ES cell-somatic 
cell hybrids. Several reprogramming core factors have already been identified, including 
Oct4, Sox2, c-Myc, and Klf4 (OSCK). Overexpression of OSCK or OSK via virus- or nonvirus-
mediated gene transformation can reprogram mouse and human somatic cells into 
pluripotential cells; cells reprogrammed through this means are known as iPS cells 
(Nakagawa et al., 2008; Takahashi et al., 2007a; Takahashi et al., 2007b; Takahashi & 
Yamanaka, 2006). The use of this in-vitro somatic reprogramming technology to produce 
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human iPS cells is expected to be the long-awaited breakthrough that will allow researchers 
to produce syngenic tissue cells from personalized stem cells obtained from patients who 
require tissue-cell transplants. In the clinical setting, the propensity of iPS cells to form 
tumors is the main problem remaining to be solved, but functional somatic cells derived 
from human iPS cells could contribute to in-vitro analysis. Human iPS cells are currently 
regarded as a promising tool, satisfying the pharmacological industry‘s need for scalability 
and physiological relevance. Many researchers are planning to acquire patient-specific 
human iPS cell lines from somatic cells carrying genetic dysfunctions in order to develop 
medical compounds or gene therapies that reduce the symptoms associated with these 
genetic dysfunctions. Primary cultured somatic cells derived from patients are now 
becoming available from cell banks, helping us to produce models of gene therapy or 
chromosome-mediated therapy based on human iPS cells. Some kinds of biological analysis 
require accurate assessment of the phenotypic and physiological differences between 
normal cells and genetically affected cells in an identical genetic background. Even if normal 
cells were available from a patient with a genetic dysfunction, it might be difficult to 
compare the iPS cell line established from the affected tissue with that established from 
neighboring unaffected tissue because of the wide clonal variation among the iPS clones 
established through factor-mediated reprogramming. Thus genetically manipulated 
pluripotential cells created through knock-out, knock-in, transgene, or another molecular 
engineering technology might still provide some advantage over iPS cells because normal 
controls for the manipulated cells are always available. 
3. General chromosome manipulation tools 
3.1 Cre-loxP system 
The Cre-loxP system is particularly useful for creating new chromosomes carrying site-
specific deletions, duplications, inversions and translocations. A single loxP site contains 
two 13-bp inverted repeats (5’-ATAACTTCGTATA-3’ and 5’-TATACGAAGTTAT-3’) 
flanking an asymmetric 8-bp core sequence (5’-GCATACAT-3’). The central core sequence 
defines the orientation of the loxP site. Thus the core sequence in inverted-loxP can be 
described as 5’-ATGTATGC-3’. One Cre (causes recombination) recombinase monomer 
binds each inverted repeat. The synaptic complex is first formed through dimerization of the 
loxP-bound Cre molecules, and then Cre catalyzes DNA strand exchange between the 
homologous core regions via a Holliday intermediate. Only when two sites are placed as 
direct repeats on the same DNA strand does Cre induce restricted deletion of the DNA 
placed between the two loxP sites. Using this system, the targeting of a specific undesired 
DNA sequence can be Cre-dependently induced in a specific tissue type or cell type both in 
vivo and in vitro (Branda & Dymecki, 2004; Mills & Bradley, 2001). The Cre-loxP system also 
enables the induction of chromosome-wide recombination in cis, leading to megabase 
deletion, and can induce interchromosomal exchange between any loxP-tagged 
chromosomes, resulting in targeted chromosomal reciprocal translocation. Such in-trans 
recombination is induced to allow transfected exogenous sequences to integrate into the 
host genome through mitotic recombination at loxP sites (Figure 1A). 
In addition from the experimental machinery, a native cellular mechanism for mitotic 
recombination exists in mammalian cells. For spontaneous mitotic recombination to occur, 
two DNA strands possessing high similarity first align spontaneously in a nucleus and then 
are exchanged through the repair of spontaneous DNA double-strand breaks between them.  
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Fig. 1. Chromosome engineering technologies by means of Cre-loxP system. (A) Targeted 
insertion of loxP sites is practically used to induce a chromosome-wide deletion or a 
reciprocal translocation. Using sequential gene targeting, two loxP sites are introduced into 
two regions on the same or different chromosomes, resulting in chromosome-wide deletion 
or chromosome translocation, respectively. A loxP are often combined with 5' portion of a 
marker gene, while the other one are combined with the remaining portion of the marker 
gene. The marker genes reconstructed by exon fusion permit cell growth of the Cre 
recombinants. The Cre-loxP system is also applied to induce chromosome translocation 
between a desired chromosomal segment and an HAC vector. (B) Cre-inverted loxP system 
is used to induce elimination of the targeted chromosomes in the living cells. This system 
often induces inversion of the DNA region that has been placed between two loxP sites. 
When two different chromosomes are targets of mitotic recombination, the daughter cell 
received a new recombinant created through balanced reciprocal translocation. In other 
cases, mitotic recombination causes the production of daughter cells carrying uniparental 
disomy. Even if recombinant cells do not contain any genetic imbalance, uniparental disomy 
sometimes causes detrimental effects because of the genomic imprinting phenomenon in 
mammals. Genomic imprinting, also known as epigenetic marking, leads to exclusive 
uniparental expression of the imprinted genes. Thus, uniparental disomy of imprinted 
regions causes either overexpression or nonexpression of the imprinted genes.  
3.2 Cre-inverted loxP system 
In the Cre-inverted loxP system, on the other hand, where the core sequence of the second 
loxP site is inverted, the DNA array placed between two loxP sites is often inverted through 
parallel synapses and recombination at the loxP sites located on the same DNA strand (Spitz 
et al., 2005). This inversion event yields intact recombined loxP sites, which will become 
targets of the second recombination. Moreover, Cre can initiate recombination between the 
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loxP sites located on a pair of sister chromatids, resulting in derivation of a dicentric 
chromosome and an acentric chromosome. The subsequent cell divisions yield an 
accumulation of cells exhibiting targeted chromosomal loss (Lewandoski & Martin, 1997) 
(Figure 1B). We have developed CEC plasmid vectors containing a pair of loxP sites in an 
inverted orientation, which reproducibly induced hemizygous or homozyous loss of CEC-
tagged chromosomes (Matsumura et al., 2007; Otsuji et al., 2008). To isolate transformants of 
CEC, a ubiquitously expressed drug-resistant gene and a green fluorescent protein (GFP) 
reporter gene were inserted in the into the Cre-inverted loxP sequence.  
4. Chromosome elimination in mouse pluripotential cells 
In mammalian cells, chromosome composition and gene dosage are kept stable, and large-
scale chromosome-wide deletions are usually fatal. To create a non-fatal large-scale 
chromosomal imbalance, we applied the Cre-inverted-loxP system to tetraploid hybrid cells 
derived from mouse ES cells and somatic cells. As a first step, we prepared multiple stable 
CEC transformants of mouse ES cells, in which CEC-tagged chromosomes become targets of 
selective elimination. In the Cre-inverted loxP system, where the core sequence of the 
second loxP site is inverted, the inverted loxP sites are able to form parallel synapses 
between sister-chromatids after DNA synthesis, which produce a dicentric chromosome and 
an acentric chromosome as Cre-induced recombination products (CRPs). The CRPs are 
visible in many metaphases one to three days after Cre treatment. As a consequence, CRPs 
are eliminated in the course of the cell divisions that follow (Figure 1B). Such targeted 
chromosomal loss has been induced in progeny carrying a Y-transgene and containing an 
accidentally inverted loxP within a multi-copy array of directly repeated loxP sites 
(Lewandoski & Martin, 1997). Thus conditional elimination of targeted chromosomes might 
be technically inducible in mice, though viable offspring cannot be expected if any one of 
the intact autosomal chromosomes is eliminated. 
4.1 Chromosome elimination cassette (CEC) 
The CEC contains a ubiquitously expressed GFP-encoding gene and a drug-resistant gene 
between a loxP site and an inverted loxP site. The reporter genes were intended to allow 
researchers to isolate CEC-transformants as GFP-positive and drug-resistant cells, while Cre 
recombinants missing CEC-tagged chromosomes can be selectively obtained as GFP-
negative cells through fluorescence activated cell sorting (FACS). Each sorted cell can be 
clonally expanded as an independent Cre-recombination product for further analysis.  
4.2 Methods 
4.2.1 CEC-tagging 
Two kinds of CECs and their transgenic ES cell lines have been created: pCEC-CAG-
gfp/IRES.puro-pA (CECpuro) and pCEC-Pgk-neo/IRES.gfp-pA (CECneo). The linealized 
DNAs of CECpuro and CECneo were electroporated into mouse ES cells to allow for the 
isolation of transformants through purimycin and G418, respectively. The transformants of 
linealized CEC vector DNA were isolated from HM1 mouse ES cells (129/Ola: Mus musculus 
domesticus) deficient in the Hprt gene. In such cases, CEC can be introduced into the desired 
part of the chromosome by homologous recombination. Thus fused cells created from 
mouse ES cells and wild-type somatic cells were isolated by means of HAT selection 
medium. All of the stable transformants were analyzed for their CEC-integration sites using 
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the fluorescence-in-situ-hybridization (FISH) method. The location of FISH signals was 
determined on the basis of the G-banded pattern of the chromosomes. By now, CEC 
integration sites have been observed on 13 chromosomes out of the 19 pairs of autosomes 
and sex chromosomes of laboratory mice. These mapping data and chromosome 
identifications have been reported previously (Tada et al., 2009). The CEC-tagged 
chromosomes could be future targets for creating monosomy or uniparental disomy in a 
Cre-dependent manner. 
4.2.2 Whole cell fusion 
ES cell-like hybrid cells derived from mouse ES cells and mouse somatic cells are obtained 
by means of electric fusion followed by HAT selection. The electric fusion protocol has been 
described previously (Tada & Tada, 2006a, b). Only Hprt-positive cells can grow in HAT 
selection medium, so its use results in selective growth of the fused cells derived from Hprt-
negative ES cells and wild-type somatic cells. Hybrid cells derived from CECneo-transgenic 
ES cells and CECpuro-transgenic ES cells can be isolated through co-treatment with G418 
and puromycine after electric cell fusion. JF1 mice possessing a Mus musculus molossinus 
genetic background were often used as somatic cell donors so that the origin of the 
chromosomes derived from somatic cells in the tetraploid cells could be determined. 
4.2.3 Cre treatment 
The Cre expression vector pCMV-cre (Gibco-BRL, Invitrogen, Carlsbad, CA, USA) was 
modified into pCAG-cre and then transfected into CEC-tagged mouse ES cell hybrid cells by 
means of Lipofectamine™ 2000 (Invitrogen) or Nucleofector® (Amaxa, Basel, Switzerland). 
The best program and DNA content for nucleofection were A13 and 5 mg of DNA to 2x106 
cells. A high transfection rate was obtained: more than 60% of surviving cells showed 
transgene expression within one day after nucleofection. Consistent with this data, efficient 
induction of CRPs of CEC chromosomes was recorded one day after nucleofection. Further, 
multi-day culture yielded an accumulation of cells missing CEC-tagged chromosomes. 
4.3 Whole chromosome elimination 
First, we attempted single chromosome elimination in CECpuro transformants of mouse ES 
cell hybrid cells with mouse somatic cells (Matsumura et al., 2007). After conventional 
lipofection of the Cre expression vector, GFP-negative cells were isolated by FACS. All 
clones proliferated from a single GFP-negative cell were used for FISH analysis. The results 
clearly showed that CEC-tagged chromosomes were selectively eliminated in a Cre-
dependent manner. Next we attempted to eliminate two chromosomes at once (Otsuji et al., 
2008). We generated four sets of fusion clones derived from CECpuro-tagged mouse ES cells 
and CECneo-tagged mouse ES cells through cell selection with G418 and puromycin. In the 
case of the fused mES cells containing both CECpuro-tagged chromosome 12 and CECneo-
tagged chromosome 17 (CEC12/17), flowcytometric analysis after conventional lipofection 
of the Cre expression vector showed only a 5% increase in GFP-negative cells in 7-day-old 
cultures. After nucleofection of the Cre expression vector, in contrast, nearly 50% of Cre-
treated cells were GFP-negative hybrid cells. FACS-mediated isolation of GFP-negative cells 
was successively achieved by recovering the 78,XXYY, -12, -17 cell clones as Cre-
recombinants with 96% purity from 80,XXYY tetraploid cells containing four chromosome 
12s and four chromosome 17s. Similarly, we detected the loss of one set of chromosomes 
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each from CEC11/17, CEC6/11 and CEC6/12 through FISH chromosome painting. In these 
hybrid cells, asynchronous chromosomal loss was also observed, even though two CEC 
regions were exposed to Cre activity in the same nucleus. This asynchrony gradually 
decreased over 5 days, however. In any case, following the DNA replication stages will 
provide Cre enzymes with access to loxP sites. As a next step, we need to precisely identify 
the kinds of autosomes to which chromosome elimination technology can be applied. 
4.4 Homozygotic chromosome elimination 
CEC6 mouse ES cells were created by means of the homologous recombination technology 
known as knock-in, through which CECneo vector was inserted into the Rosa26 locus on 
mouse chromosome 6 (Matsumura et al., 2007). We prepared mouse ES cells that were 
homozyous for a CEC-tagged region through either mitotic recombination between 
homologous chromosomes or a combination of loss of wild-type chromosome and 
duplication of CEC-tagged chromosomes. Because there are two expressed copies of neo in a 
CECneo transformant, the homozygotes created from this transformant can be grown in the 
presence of high doses of G418. Using this system, we tried to demonstrate that the 
reprogrammed chromosome 6s derived from JF1 somatic cells could maintain an 
undifferentiated state without mouse ES cell-derived chromosome 6s as mentioned above.  
Cre recombinants missing both copies of chromosome 6s derived from mouse ES cells only 
expressed Nanog mRNA from JF1-derived chromosome 6s, and maintained their 
pluripotency. This fact clearly demonstrates that reprogrammed somatic chromosomes can 
functionally replace the ES chromosomes in hybrid cells derived from mouse ES cells and 
somatic cells. For tetraploid cells to survive and maintain their self-renewing potency, 
however, three copies of chromosome 6s were likely to be required. We found that every 
Cre-transformant possessed three chromosome 6s due to spontaneous duplication of 
somatic chromosome 6. Thus epigenetic reprogramming of the somatic cell–derived Nanog 
gene is sufficient, but the group of genes encoding chromosome 6 including Nanog might be 
sensitive to gene-dosage regulation.  
4.5 Partial chromosome deletion 
Theoretically, in the Cre-inverted loxP system, partial chromosomal deletions are not 
expected. Nevertheless, more than 30% of CEC6 mouse ES cells were observed to have 
turned into GFP-negative cells in 5-day-old Cre recombinants due to partial deletion, 
whereas whole chromosomal loss occurred at low frequencies (around 5%). It is therefore 
evident that the frequencies of regional mitotic recombination between short identical 
sequences in the genomic region of chromosome 6s are enhanced via a scaffold formation 
through Cre-mediated antiparallel cohesion between loxP sites (Otsuji et al., 2008). Thus a 
small deletion is less likely to be fatal; in fact, some diploid Cre recombinants isolated from 
CEC6 mouse ES cells maintained their self-renewing potencies and expressed both Nanog 
and Oct4. The Rosa26 locus occurs close to the mouse von Hippel-Lindau tumor suppressor 
gene Vh1h, an orthologue of human VHL, which is located on human chromosome 3p25.5. 
Null mutation coupled with germline mutation and chromosomal deletion of the VHL gene 
have been reported in familial VHL syndrome, which predisposes affected persons to 
malignant or benign tumors (Maher & Kaelin, 1997; McGrath et al., 1992; Latif et al., 1993). 
Based on these cytogenetic reports, VHL syndrome is also known as 3p- syndrome (Sherr, 
2004). In mice, heterozygotic loss of Vhl1 is sufficient to predispose affected mice to vascular 
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tumors, while homozygous loss causes embryonic lethality (Gnarra et al., 1997; Haase et al., 
2001). Therefore CEC-tagged mouse ES cell clones may provide materials with which to 
create a loss of heterozygosity (LOH) model in vitro or in vivo by a combination of genetic 
mutation and inducible chromosomal deletion. We have already isolated several CEC-
tagged mouse ES cell clones in which CEC-tagged regions are located near tumor 
suppressor genes, including BRACA1 or TP57 in CEC11Dpuro, BRACA2 in CEC5puro, P16 
and TP73 in CEC4neo, TP53 in CEC7neo, and VHL in CEC6neo (Tada et al., 2009). In large 
chromosomal imbalances, the regions of insertion and deletion disrupt the complex 
interactions of many genes, not only within the chromosomal domains but also in other 
regions (Stallings, 2007). Thus chromosome-wide deletion technology might provide more 
information than simple gene disruption does as a model of deletion-mediated diseases in 
humans.  
4.6 Future research 
It has previously been shown that the frequency of mitotic recombination is about 100 times 
lower in mouse ES cells than it is in adult somatic cells or in isogenic mouse embryonic 
fibroblasts (Cervantes et al., 2002). Homozygous loss also takes place due to uniparental 
disomy induced either by sequential events of mitotic recombination and X segregation or 
by loss of functional chromosomes and duplication of the affected chromosomes. In LOH 
events in somatic cells, mitotic recombination predominates over uniparental disomy 
initiated by loss-and-duplication, for which a high level of nucleotide sequence homology is 
required. Despite the importance of chromosomal recombination in the LOH diseases, little 
is known about the properties of the junctions involved in the chromosomal rearrangements 
or about the responsible enzymes, because of the difficulty of inducing chromosomal 
deletion in vitro and in vivo. In this Cre-inverted loxP system, however, Cre significantly 
enhanced local rates of recombination at CEC-tagged regions. This may help to resolve the 
correlation between intra-chromosomal deletion events and either the flexibility of 
chromatin or the accumulation of junction sequences responsible for mitotic recombination. 
The application of CEC technology to diploid cells could help to isolate recombinants as 
GFP-negative clones passing through mitotic recombination more frequently rather than 
undergoing spontaneous recombination. This might promote better understanding of the 
modulator sequences responsible for the tangle structure formation and its solution 
mechanism that induces mitotic recombination leading to chromosomal deletions. It is clear 
that Cre-mediated cohesion enhances the rate of intra-chromosomal recombination in this 
region, but Cre is probably not involved in DNA strand exchange. Identifying the cellular 
factors that catalyze these recombination events will help resolve the mechanisms 
underlying the progression of cancers through chromosomal rearrangements. 
5. Chromosome transfer into pluripotential cells 
In early gene manipulation techniques, mRNA coding regions were introduced and 
ubiquitously expressed in a given set of cells. As a next step, endogenous transcriptional 
regulatory elements were connected to the open reading frames of the genes and used for 
developmental or tissue-specific expression. Now, to mimic the physiological expression 
profile of a certain gene, 100 kilobasepairs of genomic DNA are introduced into mammalian 
cells using bacterial artificial chromosome (BAC), P1-bacteriophage artificial chromosome 
(PAC), or Yeast artificial chromosome (YAC). Recently, there has arisen a need to realize the 
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development of larger-capacity carriers for genes or gene clusters spanning a genomic 
region as large as a megabase. In one example, a chromosomal region comprises a major 
part of the gene function shared by many genes classified as a gene family. In another 
example, splicing forms are regulated tissue-specifically, so that a single form may be 
functionally divergent when expressed in different tissues. In immunoglobin genes, 
moreover, VDJ segments are recombined from a vast variety of the choices aligned in 
tandem over a wide chromosomal region. To induce VDJ recombination against a specific 
immunogen under physiological conditions, this whole chromosomal region should be 
introduced to the host cells to make them suitable for further use. Thus the development of 
a chromosome-wide gene transfer system would bring researchers a new genetic tool to 
analyze a proper function as seen in vivo. Human chromosome segments have been 
introduced not only into human host cells but also into mouse, avian, and other types of 
host cells. It is evident that human chromosome segments function in the trans-chromosome 
mice that are created via trans-chromosome mouse ES cells. There have recently been 
preliminary reports claiming the creation of transchromosomic animals producing a diverse 
repertoire of human immunoglobulin (Kuroiwa et al., 2002; Tomizuka et al., 2000; Tomizuka 
et al., 1997). Theoretically, depending on the size and region of the chromosome segment in 
question, an extra chromosome can contribute to half of the progeny through meiosis. 
5.1 Chromosome manipulation 
Centromeres, together with telomeres, are essential for segregation during cell division in 
any eukaryotic chromosome. Telomere function is also required in each of the ends to 
ensure chromosomal stability. Thus, chromosomal vectors have been created as “mini-
chromosomes“, each containing a short chromosome segment containing a loxP site, a 
human chromosome-derived centromere, and two telomere ends enclosing them. A 
telomere consists of an array of short tandem repeats, (TTAGGG)n in humans, which form a 
closed loop and protect chromosome ends. Through targeted insertion of telomere repeats, a 
new chromosome end can be created at a desired position in the chromosome. Native 
centromeres from human chromosomes that are involved in vectors are likely to behave as 
endogenous chromosomes. Vectors containing such chromosomes are called human 
artificial chromosome (HAC) vectors. 
5.2 Human artificial chromosome (HAC) vector 
A loxP site has been introduced into the HAC to allow for Cre-mediated site-specific 
insertion of circular DNAs at the beginning of the HAC (Dieken et al., 1996; Kuroiwa et al., 
2000). Transgenes can therefore be introduced into these loxP sites by Cre-mediated lateral 
recombination with a loxP site located on a plasmid-, BAC-, or PAC-vector. The acceptor 
loxP site on the HAC can later be used for various purposes, such as a platform for 
megabase-level chromosomal segments. To insert the desired chromosomal segment into 
the HAC, one end of each defined chromosomal region is truncated by telomere insertion, 
while the other end is tagged by a donor loxP site. The loxP-tagged intact or truncated 
chromosome is introduced into the HAC-containing host cells. Transient Cre expression is 
then able to combine an HAC and a donor chromosomal segment at a loxP site, leading to 
the creation of an HAC containing an extra-chromosomal segment. Recombinants can be 
selectively grown through culturing with drugs to create a complete drug-resistant gene by 
exon fusion technology. HACs can be introduced into mouse ES cells through MMCT 
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(Fournier & Ruddle, 1977; Koi et al., 1989) as a cell fusion product (Figure 1A). For further 
in-vitro use, HAC transformants could be created using human ES cells and iPS cells. 
5.3 Microcell-mediated chromosome transfer 
First, to manipulate the donor chromosomes, normal mouse or human cells are fused with 
DT40 cells, on which targeting-mediated genetic manipulation is performed. Next, the 
manipulated donor chromosome is transferred from the DT40 hybrids to the HAC-
containing CHO cells by MMCT technology (Kuroiwa et al., 2000). Usually, HAC is 
maintained in the CHO cell line, which is a more capable microcell donor. When the HAC 
uses a centromere of human chromosome 21, the HAC vector is originally constructed in the 
DT40 hybrid cells, in which intact human chromosome 21 is introduced from human 
fibroblasts through cell fusion (Katoh et al., 2004). The HAC vector recombined through Cre 
treatment is maintained in CHO cells. Again, the constructed HAC vectors containing donor 
chromosomal segments are transferred from CHO cells to other recipient cells (Kugoh et al., 
1990) such as mouse A9 cells, mouse ES cells, or the other multipotent or pluripotent cells 
through MMCT using standard procedures. 
5.4 Trisomy 21 
Trisomy 21, the most common live-born human aneuploidy, causes Down's syndrome (DS), 
which encompasses many clinical phenotypes including a reduced incidence of solid 
tumors. An extra copy of human chromosome 21 has been introduced into mouse ES cells 
through MMCT (Shinohara et al., 2001). The authors showed that the progeny of these 
chimeric mice were able to contain human chromosome 21-containing cells after small-scale 
deletion. Chimeric mice showed various degrees of mosaicism as regards the retention of 
human chromosome 21, and there was a high correlation between the retention rate of 
human chromosome 21 in the brain and impairment in learning or emotional behaviors. 
Hypoplastic thymus and cardiac defects were also reported in a considerable number of 
chimeric mouse fetuses, with a high contribution of human chromosome 21 in mouse 
somatic cells. Recently, another group has reported a trans-chromosomic mouse model of 
DS in which tumor angiogenesis is significantly repressed; in particular, in-vitro and in-vivo 
angiogenic responses to vascular endothelial growth factor (VEGF) are inhibited by 
overdose of a set of identified factors transcribed from the three-copy alleles (Reynolds et al., 
2010). The evidence shows that some human genes are able to reproduce their physiological 
functions in mouse cells. 
5.5 Functional compensation through additional chromosome segments  
As mentioned above, Oshimura and colleagues have developed a large number of HAC 
applications for biological analysis in the fields of cancer research, DNA repair, telomere 
research, genomic imprinting, and others. Moreover, they have shown that HAC vector 
could be used for gene therapy to correct insulin deficiency in mice (Suda et al., 2006) and 
Duchenne muscular dystrophy (DMD) in mice and in human immortalized mesenchymal 
stem cells (Hoshiya et al., 2009). The DMD-HAC also functionally replaced the affected 
allele in a mouse DMD model and in patient iPS cells (Kazuki et al., 2010). Therefore,  
the combination of patient-specific iPS cells and an HAC containing the responsible  
genes represents a powerful tool for gene and cell therapies. As previous cases have 
demonstrated, HAC technology may enable us to create animal models using native human 
chromosomes. 
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6. Future research 
In the recent successful applications of this technology, human chromosomal regions were 
transmitted stably to mouse progeny, resulting in the creation of humanized mice for 
desired chromosomal regions, as mentioned above. An important point to consider is that 
horizontal chromosome transfer can realize the exchange of genetic material between 
different strains and species without producing offspring. Combined with chromosome-
wide elimination by means of the Cre-inverted loxP system and chromosome transfer 
technology, the creation of consomic mice derived from different strains might be possible. 
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